Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10421945

    Agents and methods to elicit anti-tumor immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10420799

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10420747

    Cancer treatment method using ailanthone compounds

    EAST CHINA NORMAL UNIVERSITY · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10415015

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10413540

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10416163

    Method and treatment of recurring endometrial cancer with an inhibitor of USP14

    Regents of the University of Minnesota · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10414771

    Compounds useful for inhibiting metastasis from cancer and methods using same

    Alliance Discovery, Inc. · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10406125

    Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject

    ADVANCED BIODESIGN · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10406248

    Molecular imaging of cancer cells in vivo

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10398734

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10400010

    Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10398661

    Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers

    The Board of Regents of the University of Texas System · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10398778

    Method for enhancing specific immunotherapies in cancer treatment

    Providence Health & Services—Oregon · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10399962

    Azolopyrimidine for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10400045

    Internalizing human monoclonal antibodies targeting prostate and other cancer cells

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10392441

    IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10392412

    Platinum anticancer agents

    The Regents of the University of California · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10383943

    Compositions and related methods for the treatment of cancer

    SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10376510

    2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10378058

    Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10364295

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10363247

    (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

    Karyopharm Therapeutics Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10363273

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10357477

    Anticancer compounds

    Regents of the University of Minnesota · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10357539

    Use of peptides that block metadherin-SND1 interaction as treatment for cancer

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10350239

    Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

    Propanc Pty Ltd · Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10345310

    Diagnostic test for early stage cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10344096

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10342815

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10335365

    Bladder cancer specific ligand peptides

    The United States of America as represented by the Department of Veteran Affairs (Washington DC) · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10335404

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10335382

    Use of hydrogen sulfide synthesis inhibitors for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10329353

    Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells

    The Board of Regents of the University of Texas System · Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10322113

    Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same

    The Board of Regents of the University of Texas System · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10316038

    Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10314810

    Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics

    Northwestern University · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10316050

    PT (IV) complexes containing 4,4′-disubstituted-2,2′-bipyridyl and their use in cancer therapy

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10307410

    Mcl-1 modulating compounds for cancer treatment

    INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10308698

    Therapeutic targeting of SET1B/compass pathway for treating cancers

    Northwestern University · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10301314

    Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10300150

    Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells

    Aura Biosciences, Inc. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10293037

    DNA vaccine for use in pancreatic cancer patients

    Vaximm AG · Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10292979

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10285986

    Compounds and anti-tumor NQO1 substrates

    The Board of Regents of the University of Texas System · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10287297

    Epoxyazulene derivatives useful for treating cancer and diabetes

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10278976

    Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors

    MIRA DX, INC. · Granted Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10273281

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10273299

    Antibodies to tumor endothelial marker 8

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.